Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUILIBRIUM-ADCS
2025-522648-42-01Phase 3Authorised
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of atumelnant in ACTH-dependent Cushing's syndrome and Corticotropin adenoma (ACTHoma) (3 arms), sponsored by Crinetics Pharmaceuticals. Planned start Sep 2026; status: authorised.
02
Drugs
atumelnant
03
Conditions
ACTH-dependent Cushing's syndromeCorticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2025-522648-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522648-42-01.